Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Cost Reimbursement
Drugs
Locations
Clinical Specialty
1-20 of 991 trials

Urothelial Cancer: Disitamab Vedotin with Pembrolizumab

We are studying the effects of disitamab vedotin alone or with pembrolizumab in patients with HER2-positive urothelial cancer. This trial aims to see if these treatments can improve outcomes for those with advanced disease.

Bladder CancerEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Alzheimer's Disease and Down Syndrome: ACI-24.060 Study

We are testing a new treatment, ACI-24.060, to see if it is safe and can help generate an immune response in people with early Alzheimer's and adults with Down syndrome. This study will also look at its effects on brain amyloid levels.

Alzheimer's Disease>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPsychiatry

Nalmefene for Reducing Cravings in Behavioral Addictions

We are studying whether nalmefene can help reduce craving intensity in people with behavioral addictions, such as gambling and food addiction, when added to their usual treatment.

Behavioural AddictionConfirmation phase (III)≤5 visitsStandard MedicinesCost Reimbursement

Corneal Transplantation: Optimized Immunosuppression Study

We are testing new immunosuppressive protocols for patients receiving corneal transplants to see if they can reduce eye pressure and cell loss. We also want to understand patient experiences and the cost-effectiveness of these treatments.

Corneal Graft Failure1-2 yearsMonitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementOphthalmology

Coronary Artery Disease Screening: Heart CT in Type 2 Diabetes

We are studying whether a heart CT scan can help find early signs of heart disease in people with type 2 diabetes. This may lead to better treatment options and improved heart health.

Type 2 DiabetesMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementCardiologyDiabetologyEndocrinology

Kidney Transplant: Imlifidase for Highly Sensitized Children

We are studying whether imlifidase can help children with high sensitization receive a kidney transplant by improving compatibility with the donor. This trial will also look at kidney function and overall safety of the treatment.

Kidney Transplant Rejection>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineNephrology

Diabetic Foot Infections: Contezolid Treatment Study

We are studying a new treatment called contezolid for adults with moderate to severe diabetic foot infections. The goal is to see if it is safer and more effective than the current standard treatment, linezolid.

Diabetic Foot Infection≤3 monthsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyInfectious Diseases

Epidermolysis Bullosa: ABCB5+ Stem Cell Treatment

We are studying a new stem cell therapy for individuals with recessive dystrophic epidermolysis bullosa. The trial aims to see if this treatment is safe and effective compared to a placebo.

Epidermolysis Bullosa1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteDermatologyInternal Medicine

End-Stage Kidney Disease: CSL300 Treatment Study

We are investigating whether different doses of CSL300 can help reduce inflammation in adults with end-stage kidney disease undergoing dialysis. This study aims to understand its potential effects on heart health.

Atherosclerotic Cardiovascular Disease1-2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsInvestigational MedicinesCost ReimbursementCardiologyInternal MedicineNephrology

Parkinson's Disease: ACI-7104.056 Vaccine Study

We are testing a new vaccine to see if it is safe and can help improve symptoms in people with early-stage Parkinson's disease. The study will also look at how the vaccine affects certain biological markers related to the disease.

Early Stages of Parkinson's Disease>2 yearsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Chronic Lymphocytic Leukemia: Venetoclax and Epcoritamab Study

We are studying a combination of venetoclax and epcoritamab in patients with relapsed or refractory CLL or SLL. The goal is to see if this treatment improves disease control and overall survival compared to existing options.

Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Crohn's Disease: Comparing Biological Therapies After Surgery

We are studying two ways to start biological therapy after surgery for Crohn's disease to see which better prevents disease recurrence. This trial involves adults who have had an ileocolonic resection.

Crohn's Disease1-2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyInternal Medicine

Etrasimod for Adolescents with Ulcerative Colitis

We are studying whether etrasimod can help adolescents aged 12 to 17 with moderately to severely active ulcerative colitis achieve remission. The trial will also look at the safety and how the body processes the medication.

Ulcerative Colitis1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

Prostate Cancer: Abemaciclib with Abiraterone

We are studying whether adding abemaciclib to standard treatment improves outcomes for men with prostate cancer that has spread and is responsive to hormonal therapy. The trial also evaluates safety and patient quality of life.

High-Risk Metastatic Hormone-Sensitive Prostate CancerConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Marstacimab for Severe Hemophilia A and B

We are studying the long-term safety and effectiveness of marstacimab in people aged 1 to 75 with severe hemophilia A or B, with or without inhibitors. This research aims to improve treatment options for managing this condition.

Haemophilia>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematology

Advanced Breast Cancer: ARV-471 vs Fulvestrant

We are studying a new medication, ARV-471, to see if it works better than fulvestrant for patients with advanced estrogen receptor-positive, HER2-negative breast cancer. This trial is for those whose cancer has progressed after prior treatments.

Advanced Breast CancerConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

BOTOX for Masseter Muscle Prominence

We are studying whether BOTOX injections can help reduce the prominence of the masseter muscle in adults. This trial compares BOTOX to a placebo to evaluate its effectiveness and safety.

Masseter Muscle Prominence1-2 yearsConfirmation phase (III)11-15 visitsStandard MedicinesCost ReimbursementDermatology

Ikervis for Atopic Keratoconjunctivitis

We are studying whether Ikervis, applied four times a day, can effectively treat atopic keratoconjunctivitis. This trial aims to see how well it works compared to a placebo.

Atopic Keratoconjunctivitis3-6 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementOphthalmology

Oligometastatic Solid Cancer: SBRT with ATRA Support

We are studying a new radiation therapy combined with a drug to support the immune system in patients with oligometastatic solid cancer. This trial aims to evaluate safety and how well the treatment works.

Oligometastatic Solid Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementOncology

Chronic Kidney Disease: Amiloride Treatment Study

We are investigating whether the diuretic amiloride can help protect kidney function in people with chronic kidney disease. The study looks at its effects on kidney health and inflammation.

Chronic Kidney Disease≤3 monthsEfficacy phase (II)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineNephrology